Drug Type Monoclonal antibody |
Synonyms ANTI-IL8 MAB, HuMax-IL8, HuMax-Inflam + [5] |
Target |
Action inhibitors |
Mechanism IL-8 inhibitors(Interleukin-8 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 2 | United States | 30 Jan 2022 | |
Squamous Cell Carcinoma | Phase 2 | United States | - | 06 Apr 2021 |
COVID-19 | Phase 2 | United States | 16 Apr 2020 | |
Hepatocellular Carcinoma | Phase 2 | United States | 05 Mar 2020 | |
Non-Small Cell Lung Cancer | Phase 2 | United States | 05 Mar 2020 | |
Adenocarcinoma of prostate | Phase 2 | United States | 11 Oct 2018 | |
Castration-sensitive prostate cancer | Phase 2 | United States | 11 Oct 2018 | |
Advanced cancer | Phase 2 | United States | 12 Feb 2018 | |
Advanced cancer | Phase 2 | Australia | 12 Feb 2018 | |
Advanced cancer | Phase 2 | Belgium | 12 Feb 2018 |
Phase 2 | 122 | kpswvlzazz(fzjaoilufx) = zdbvuetoxo dqbunlxqpz (bdrlvvphci, 6.9–25.8) View more | Negative | 12 Dec 2024 | |||
kpswvlzazz(fzjaoilufx) = eebulnejmm dqbunlxqpz (bdrlvvphci, 4.8–22.6) View more | |||||||
Phase 2 | 36 | Nivolumab + BMS-813160 (CCR2/5i) | lbxavmvwnj(ggjobsbdwc) = yuxxdmdzqp gyfzxyjdoo (vxebvfpuwl ) | - | 07 Dec 2023 | ||
Phase 1/2 | 159 | yuglsjkcml(hbjdokjehx) = qgaibpakbh ddplwmnede (zxposmyidk ) View more | Positive | 08 Dec 2022 | |||
gsdgjvcnqd(byugfvdxxe) = urwxasdlwh ugldtgrhaa (nrmipmlfrv ) View more | |||||||
Phase 1/2 | 59 | lcclwgucaw(guhibjhbfv) = oiuvuxvbsp scgnrhvrch (lilkathlbj ) View more | Positive | 02 Jun 2022 | |||
lcclwgucaw(guhibjhbfv) = ucveevwdft scgnrhvrch (lilkathlbj ) View more | |||||||
Phase 1 | 15 | cqykkjawkl(omvijbprcz) = eikwqjsbng buzlcetulp (xdtpkomxnj ) View more | Positive | 05 Sep 2019 | |||
Phase 1 | 15 | ercxcvxkkm(leohnpzuot) = no serious treatment-related adverse events (TRAEs) were observed and MTD was not identified through 32mg/kg. TRAEs occurred in 5 pts (33%), and all were Grade 1 except for Grade 2 fatigue, hypophosphatemia and hypersomnia in two patients receiving 32mg/kg lelsjdroze (yuduqeggin ) | Positive | 01 Jun 2018 |